Literature DB >> 3150252

Methods for thymidylate synthase pharmacodynamics: serial biopsy, free and total TS, FdUMP and dUMP, and H4PteGlu and CH2-H4PteGlu assays.

C P Spears1, B G Gustavsson.   

Abstract

This report details our methods for performance of the major parameters related to quantitation of TS inhibition resulting from fluoropyrimidine administration to patients, methods equally applicable to preclinical studies. Sampling of tumors before and after drug treatment is done by 4 mm disposable punch biopsy or forceps biopsy via subcutaneous tunneling. Homogenates are prepared using N2 or polytron-mincing. Cytosolic free TS is measured by either the tritium-release method for small biopsies or by [3H]FdUMP ligand-binding. FdUMP and dUMP are separated by DEAE-cellulose column and measured by competitive binding and [14C]dTMP synthesis by the Moran methods. Total, post-FUra TS is measured by pre-incubation dissociation of FdUMP-bound TS after neutral charcoal removal of cytosolic ligands. H4PteGlu and CH2-H4PteGlu are measured by the Priest method using L. Casei TS. The materials and methods are described in sufficient detail to permit wide application of this approach.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3150252     DOI: 10.1007/978-1-4684-5607-3_9

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  8 in total

1.  Antisense-induced down-regulation of thymidylate synthase and enhanced cytotoxicity of 5-FUdR in 5-FUdR-resistant HeLa cells.

Authors:  P J Ferguson; J M DeMoor; M D Vincent; J Koropatnick
Journal:  Br J Pharmacol       Date:  2001-12       Impact factor: 8.739

2.  Antisense down-regulation of thymidylate synthase to suppress growth and enhance cytotoxicity of 5-FUdR, 5-FU and Tomudex in HeLa cells.

Authors:  P J Ferguson; O Collins; N M Dean; J DeMoor; C S Li; M D Vincent; J Koropatnick
Journal:  Br J Pharmacol       Date:  1999-08       Impact factor: 8.739

Review 3.  Clinical pharmacology of 5-fluorouracil.

Authors:  R B Diasio; B E Harris
Journal:  Clin Pharmacokinet       Date:  1989-04       Impact factor: 6.447

4.  Impact of the oxaliplatin-5 fluorouracil-folinic acid combination on respective intracellular determinants of drug activity.

Authors:  J L Fischel; P Formento; J Ciccolini; P Rostagno; M C Etienne; J Catalin; G Milano
Journal:  Br J Cancer       Date:  2002-04-08       Impact factor: 7.640

5.  Folate levels measured by LC-MS/MS in patients with colorectal cancer treated with different leucovorin dosages.

Authors:  Helena Taflin; Yvonne Wettergren; Elisabeth Odin; Kristoffer Derwinger
Journal:  Cancer Chemother Pharmacol       Date:  2014-09-20       Impact factor: 3.333

6.  A pharmacokinetic and pharmacodynamic investigation of Modufolin® compared to Isovorin® after single dose intravenous administration to patients with colon cancer: a randomized study.

Authors:  Yvonne Wettergren; Helena Taflin; Elisabeth Odin; Karl Kodeda; Kristoffer Derwinger
Journal:  Cancer Chemother Pharmacol       Date:  2014-10-24       Impact factor: 3.333

7.  Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphisms: relationships with 5-fluorouracil sensitivity.

Authors:  M-C Etienne; K Ilc; J-L Formento; P Laurent-Puig; P Formento; S Cheradame; J-L Fischel; G Milano
Journal:  Br J Cancer       Date:  2004-01-26       Impact factor: 7.640

8.  Synergistic effect of methionine-depleting total parenteral nutrition with 5-fluorouracil on human gastric cancer: a randomized, prospective clinical trial.

Authors:  N Goseki; S Yamazaki; K Shimojyu; F Kando; M Maruyama; M Endo; M Koike; H Takahashi
Journal:  Jpn J Cancer Res       Date:  1995-05
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.